Generic Name and Formulations:
Prednisolone acetate 1%, gentamicin (as sulfate) 0.3%; oph. susp; contains benzalkonium chloride.
- Advantages and Challenges of Community-Based Health Interventions Examined
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure
- Designing the Therapeutic Space: Using Layout, Color, and Other Elements to Get Patients in the Right Frame of Mind
Indications for PRED-G:
Ocular inflammation associated with infection.
1 drop 2–4 times daily; max 20mL for initial ℞.
Fungal, viral or mycobacterial infections.
Not for uncomplicated removal of foreign body. Corneal or scleral thinning. Glaucoma. Monitor for secondary infections, cataracts, and intraocular pressure in prolonged use. May mask signs of infection. Avoid abrupt cessation. Pregnancy. Nursing mothers: not recommended.
Steroid + aminoglycoside.
In prolonged use increased intraocular pressure, cataracts, corneal perforation, optic nerve damage, secondary infections. Ocular discomfort (eg, burning, stinging, hyperemia, pain, discharge, edema, irritation), visual impairment, blurry vision, foreign body sensation in eyes, dysgeusia, punctate keratitis, delayed wound healing, hypersensitivity or allergic skin reactions.
Susp—5mL, 10mL; Oint—3.5g
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds